Vliv adipocytárních hormonů (leptin a adiponectin) na predikci váhového úbytku a následného přírůstku (weight regain) by Drahoš, Jan
CHARLES UNIVERSITY IN PRAGUE 
THIRD FACULTY OF MEDICINE  
 
Department of Sport Medicine 
 
 
 
 
 
Jan Drahoš 
 
 
 
 
Adipokines (leptin and adiponectin) 
as predictors of weight loss and weight regain 
during one year period 
following the 10-week low caloric diet 
(NUGENOB study) 
 
 
Vliv adipocytárních hormonů (leptin a adiponectin) 
na predikci váhového úbytku a následného přírůstku (weight regain) 
v průběhu jednoho roku po ukončení 10-týdenní nízkokalorické diety 
(studie NUGENOB) 
 
 
 
 
 
Diploma thesis 
 
 
 
 
 
Prague, May 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Author of diploma thesis: Jan Drahoš 
Master's programme of study 
 
Advisor of the thesis: : MUDr. Jan Polák PhD 
Department of the advisor of the thesis: Department of Sport 
Medicine, 3LF 
Date and year of defence: 07.06.2010 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Written Declaration 
 
I declare that I completed the submitted work individually and only 
used the mentioned sources and literature. Concurrently, I give my 
permission for this diploma thesis to be used for study purposes. 
 
 
 
       In Prague on May 26th, 2010 
                   Jan Drahoš 
         
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgements 
 
I would like to thank to doctor Jan Polák, MD PhD for making me 
involved in his work at the department of Sport Medicine and for many 
useful tips regarding this thesis. 
 
I’d also like to thank all the other members of the team at the 
Department of Sport Medicine for all the support they have shown to me. 
 
I’d like to thank Eva Němcová who worked on the same project as 
me and help me a lot.
5 
Contents 
 
INTRODUCTION....................................................................................................7 
 
1. OBESITY.............................................................................................................8 
1.1. Introduction.......................................................................................................8 
1.2. Definition..........................................................................................................8 
1.3. Prevalence.........................................................................................................8 
1.4. Etiology.............................................................................................................9 
1.5. Complications...................................................................................................9 
1.6. Treatment – weight reduction.........................................................................12 
1.7. Weight maintenance........................................................................................16 
 
2. WEIGHT REGULATION.................................................................................18 
2.1. Major regulators..............................................................................................18 
2.2. Leptin..............................................................................................................21 
2.2.1. General description..........................................................................21 
2.2.2. Effects...............................................................................................21 
2.2.3. Epidemiology...................................................................................23 
2.3. Adiponectin.....................................................................................................24 
2.3.1. General description...........................................................................24 
2.3.2. Effects...............................................................................................24 
2.3.3 Epidemiology....................................................................................25 
 
3. NUGENOB STUDY FOLLOW-UP..................................................................26 
3.1. The Nugenob study.........................................................................................26 
3.2. Methods...........................................................................................................26 
3.3. Results.............................................................................................................29 
3.4. Discussion.......................................................................................................31 
 
CONSLUSION......................................................................................................33 
 
6 
SUMMARY...........................................................................................................35 
 
BIBLIOGRAPHY..................................................................................................40 
 
LIST OF PICTURES, TABLES AND GRAPHS..................................................44 
 
 
 
7 
Introduction 
 
For many years I was thinking of becoming an internist and I among 
all the internal subspecialties I was interested in diabetes, metabolism and 
nutrition. That made me some years ago to start volunteering in the 
laboratory of Department of Sport medicine at The 3rd faculty of Medicine 
of Charles University, as this department focuses mainly on the topic of 
overweight. So I’ve decided to use this colaboration and set myself a 
project in this laboratoy that would be a basis for my thesis. I was 
approved to participate on a follow up of a multicentric study called 
Nugenob, sponsored by the European Union which could serve as a sign 
that it’s topic is generally recognized as important. This study was focusing 
on the changes in gene expression under the influence of different 
hypocaloric meals. But except the data gathered for genetic analysis, 
there was a lot of other important information about the metabolic state of 
the subjects. The database that was created could be a source for many 
different analysis out of which I’ve been approved to perform one. The 
goal of my thesis is to have a closer look on the effect of adipose tissue 
hormons, leptin and adiponectin, and asses their part in weight loss and 
subsequent weight maintenance. That could possibly tell the doctor right 
at the beginning of weigh-loosing counselling, whether the patient is going 
to be successful using the basic treatment or whether he or she needs to 
get some extra care in order to achieve satisfactory results. 
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1. Obesity 
1.1. Introduction 
I’m starting this thesis with an introduction to the obesity issue, 
including some information about the broadly discussed topic of it’s 
treatment, i.e. weight loss but also a bit less considered but at least as 
important problem of weight maintenance.  
 
Storing fat was evolutionary useful but in the modern society it 
leads to obesity and deteriorates our health. 
 
1.2. Definition 
Obesity is a stage of increased body fat percentage. It’s most 
widely evaluated by BMI in kg/m2. Because the prognoses start to 
deteriorate with BMI of 25, this is considered a beginning of overweight 
and has clear health consequences correlate with BMI over 30, people 
who meat this criterion are classified as obese.  
 
1.3. Prevalence 
Among the US population, 30% are obese and another 35% are 
overweight. The prevalence of obesity in the US is higher among women 
and poor. Also in the Czech republic, the prevalence of obesity is higher in 
women than men, but the prevalence of overweight is higher in men than 
in women. 
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Figure 1 – Prevalence of obesity and overweight in the Czech republic 
 
 
1.4. Etiology 
Sometimes obesity can be secondary to some other underlying 
disease. It could be seen in Cushing syndrome, hypotyroidism, insulinoma 
or damage to hypophysis such as in craniopharingeoma, postraumatic or 
an immune system mediated damage. 
But most often, obesity is caused by a primary failure of body weight 
regulation, which will be discribed in the second chapter. 
 
1.5. Complications 
Obesity comes with many adverse effects on health. 
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Figure 2 – High BMI means a higher risk of diseases 
 
 
First of all it’s the insulin resistance and the risk of diabetes mellitus 
type 2 in cases where insulin resistance comes together with impaired 
insulin production. Among other contributing factors, lower levels of 
adiponectin could play a role in impaired insulin sensitivity. 
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Figure 3 – Obesity is a risk factor for T2DM 
 
 
Obesity is associated with polycystic ovarian syndrom in women 
and some less severe impairments of sexual functions in men. Obesity is a 
major risk factor for cardiovascular diseases, such as high blood pressure, 
coronary disease and congestive heart failure. 
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Figure 4 – Obesity is related with higher incidence of hypertension 
 
 
Furthermore the negative influence on respiratory function have 
been proven. Gallstones are more frequent in obese individuals and also 
some types of cancer appear more often. Not surprisingly, the joint suffer 
under an excessive body weight and thus obesity is a risk factor for 
degenerative diseases of joints. 
 
1.6. Treatment – weight reduction 
The treatment of obesity should suit each individual, thus it’s 
neccessary to gather data about each patient. First we assess patients 
obesity related history. Then we perform a physical examination among 
other to gain anthropometrical data. It is not sufficient to evaluate obesity 
only by BMI (see above). Since intraabdominal and abdominal 
subcutaneous fat is more risky, we try to evaluate it’s percentage from 
total body fat. That’s most widely done by waist circumference (measure 
above iliac crest and considered normal in European population if lower 
then 94 in men and 80 in women) or waist/ hip ratio (WHR) which is 
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abnormal if higher than 0,9 in women and 1,0 in men.  We also need to 
check for signs that could indicate that obesity is secondary to another 
disease), consider comorbid conditions and evaluate physical fitness by a 
questionnare and treadmill test and assess readiness and resistance to 
change the lifestyle using the analog scale (e.g. from 1 to 10). 
The goal of therapy is set depending on the severity of the findings. But at 
least 10% weight loss in 6 months is always considered reasonable. 
 
In milder cases we administer lifestyle changes and pharmacology 
only if comorbidities appeared, in moderate cases we administer both of 
the above stated methods and we may include even surgical treatment if 
comorbidities are diagnosed and in most severe cases, i.e. in BMI over 40, 
we use all 3 of above stated treatment methods. 
 
The lifestyle changes focus on diet, physical therapy and behavioral 
therapy. Dietary interventions include caloric restriction by 500-1000 
kcal/d, replacement of regular meals by meal replacements (such as 
prepared entrees or canned food) as it makes it easier to control the 
portion size, proper proportion of macronutrient with the standart set as 
45-65% of carbohydrates, 20-35% of fat and 10-35% of proteins. As an 
alternative could be used a low carbohydrate-high protein diet. Another 
useful concept introduced a lower caloric density foods, i.e. the same 
amount of food as eaten usually but lower in caloric content due to higher 
fiber and/or water content. A very aggressive approach is represented in 
very low calorie diet with caloric intake lower than 800 kcal/d. It’s indicated 
only in very severe cases where the patient could benefit from a rapid 
weight loss, is motivated and failed to lose weight using other conservative 
strategies. Rapid weight loss is associated with higher risk of gall stones 
formation (due to decreased proportion of biliary acids in bile) which could 
be prevented by prophylactic administration of ursodeoxycholic acid in a 
dose of 600mg/d. It’s important to make sure that the patient gets a 
recommended dose of vitamins a micronutriens, fiber and nonsaturated 
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fatty acids even over the period of above mentioned dietary intervention. It 
was proved that self monitoring (i.e. regular checking of weight on an own 
scale at home) is a positive predictor of weight outcome. [2] On the other 
hand, as a negative predictor is seen a number of previous attempts to 
loose weight. [2] 
 
Physical therapy is more successful if combined with dietary 
interventions and it seems to be very useful in weight loss maintenance. 
Recent recommendation for a general population advice to engage in a 
moderate physical ectivity for at least 30 min a day most days a week, 
preferably every day. As a weight loss strategy, the physical activity needs 
to be implemented gradually as most patient have major difficulties 
implementing exercise into their life and may need a help from exercise 
physiologist or personal trainer. A step-meter could be used to assess the 
physical activity related to activities of daily living which also plays an 
important role. The support by friends and family was shown to have a 
positive affect on weight outcome achieved by regular physical activity. [2] 
 
All of the above mentioned strategies are difficult for the patient to 
implement and keep. Thus a cognitive-behavioral therapy is essential. It 
should help the patient realize what, when, where a how should be 
implemented. That should be stated by the patient. He or she should also 
state the changes in lifestyle he or she is expecting to achieve till the next 
office visit and on the next visit, this could be checked as a indicator of a 
successful progress.  
 
Pharmacological treatment is only indicated in BMI over 27 if 
comorbidities are present of over BMI 30 even without comorbidities. It 
should be always combined with a lifestyle program that shows how to use 
these drugs as such a combination improves the results. Medication could 
be devided in 3 groups – centrally acting monoamine increasing drugs that 
lower appetite, drugs decreasing absorption of macronutrients from 
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gastrointestinal tract and drugs suppressing the endocannabinoid system. 
The only approved centraly acting agent is sibutramin, serotonin and 
norepinephrine reuptake inhibitor. It could cause mild gastrointestinal 
problems but also increases blood pressure and heart rate for which 
uncontrolled hypertension, coronary heart disease, congestive heart 
failure or history of stroke are contraindication of sibutramin. GI acting 
drug orlistat is a slowly reversible inhibitor of lipases and causes a 30% 
decrease in absorption of dietary fat. It has no systemic side effects but 
can cause gastrointestinal problem such as oily stool or more frequent 
defecation. These side effect usually decrease with time and could be also 
treated with administration of psyllium mucilloid together with orlistat. 
Endocanabinoid system acts via 2 types of receptors, CB1 found in brain 
and CB2 found on the surface of immune cells. CB1 is increasing appetite 
both directly and by regulating the action of other substances influencing 
appetite. CB1 antagonist rimonabant has been proved to be an effective 
antiobesitic agent. Unfortunatelly has side effects such as depression, 
anxiety and nausea. 
The surgical treatment is approved for the most severe cases, i.e. in 
BMI over 40 or over 35 in case of severe medical comorbidities. The 
procedures can be in general divided into 2 groups – restrictive and 
restrictive-malabsorptive. Into the first group counts laparoscopic 
adjustable silicone gastric banding. The latter includes Roux-en-Y gastric 
bypass and biliopancreatic diversion. These treatment methods proved to 
be the most efficient in cases of severe obesity and reduce weight for over 
30% in nearly 60% of patients for longer then 5 years. But restrictive-
malabsorptive procedure come with the risk of vitamin and micronutrient 
deficiency and so the patient needs to have the substances supplemented 
(B12, iron, folat, calcium, vit D etc...). 
 
Without further discussion, which could be a basis for another 
thesis, I’d just like to mention the fact observed in the past, that the weight 
loss does not always have a positive effect on patient’s prognosis in terms 
of mortality and morbidity. [3] This brings an important goal to not just find 
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an effective way of losing weight but also determining who is supposed to 
lose weight and who should rather keep it. 
 
 
Figure 5 – Weight change and mortality 
 
 
 
1.7. Weight maintenance 
So far, most of the projects focusing on weight management were 
short term, i.e. up to 6 months in duration. In range of these 6 months the 
effect of dietary or another intervention tends to seem positive. 
 
These short term studies suggested as positive predictive factors of 
weight maintenance: lower depression score, more years of weight 
maintenance. On the other hand, weight regain was correlated with 
decreased dietary restraint, increased susceptibility to overeating, small 
relapses and inconsistent dietary habits (e.g. different dietary patterns on 
weekdays and on weekends) [2] 
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But the problem is, that in a longer run, i.e. 1 year and more, which 
actually better represents the course of weight management in patient‘s 
life, most of the interventions fail to make the patient keep the weight loss 
he achieved. 
 
Since so far no predictors of a successfull weight loss and weight 
maintenance for a longer time span were investigated, we set this as a 
goal for our study. 
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2. Weight regulation 
2.1. Major regulators 
Body weight is regulated by endocrine and neural system. Changes 
in body weight are a result of the difference between energy intake and 
expenditure. The intake is regulated by appettite which is a result of action 
of hormonal, metabolic a neural agents on hypothalamus. Surprisingly, it’s 
not physical activity that influences the energy expenditure most. It’s the 
basal metabolic rate which is from a great extent fixed. 
 
Figure 6 – Energy expenditure 
 
 
Thus, influencing the body weight through changes in energy 
expenditure is somewhat slow. 
Interestingly, obese have higher basal metabolic rate but they also eat 
more than non-obese people. That may imply that if they didn’t eat more, 
they would not keep their higher weight. But if an obese person starts 
loosing weight, at the point he or she reaches his or her ideal weight, the 
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basal metabolic rate is lower then that of the people with the same BMI but 
without history of obesity. That makes it extremely difficult to maintain 
lower weight. 
 
In the regulation of body weight, adipose tissue is a very key 
element. It comprises adipocytes and vascular-stromal compartment. 
Adipocytes store lipids but also produce many substances influencing 
body weight balance, blood pressure, coagulation, inflamatory response 
etc. In the stromal compartment reside among other preadipocytes that 
evolve into adipocytes under the influence of PPAR gama. 
 
Figure 7 - Adipocyte and the substances it produces 
 
from:  Physiol. Res. 54: 133-140, 2005 
 
 
In and individual, genes seem to be a more important factor in 
development of obesity than the environment, but if considering the whole 
population, it seems to be the environment, that changed so much and 
thus influences our lifestyle in the past decades, that it made the majority 
of population to be prone to obesity. 
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Figure 8 - Average energy expenditure change from paleolite 
 
 
 
The risk factors in adult include a female gender and lower income. 
In children the risk increases with time spent watching television. Also lipid 
rich diet especially when combined with simple carbohydrates contributes 
to weight gain. Among less known and proved risk factor are sleep 
deprivation and changes in gut flora. 
The gene most important for development of obesity is the one for 
leptin. Leptin has many effects which include increase of energy 
expenditure and decreases of appetite by increasing POMC, which then 
needs to be converted by proconvertase to alfa-MSH that acts on it’s 
receptor and it’s effect decreases appetite. Failure of any of these steps or 
a disorder in one of many others regulatory pathways can cause severe 
obesity but these disorder are very rare. 
Another gene playing a major role is adiponectin. Both adiponectin 
and leptin will be further discusses in the following text. 
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2.2. Leptin 
2.2.1. General description 
Leptin is secreted from adipocytes but also from stomach 
epithelium and placenta. [4] It’s synthesis is influenced by unknown 
factors. Insulin and glucocorticoids are believed to be two of them. [4] It’s 
levels are also increased by the cell fat content [4] and it’s also in a 
positive correlation with body fat percentage. 
 
Figure 9 – Control of leptin synthesis and secretion 
 
 
 
2.2.1. Effects of leptin  
Leptin has receptors in brain, where it plays an important role in 
body weight regulation. Receptor are also found on the surface of T 
lymphocytes, vascular endothelium. [4] 
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Leptin is leading to weight loss. On one hand it’s lowering energy 
intake due to the decreased appetite. Leptin lowers the synthesis of 
stimulators of feeding behavior, NPY, agouti related polypeptide  [5] and 
endocanabinoids [6] and increases production of alfa-MSH [7] which 
promotes satiety . 
 
On the other hand leptin increases energy expenditure. It elevates 
body temperature and oxygen consumption and by decreasing the amount 
of fat tissue it increases energy expenditure neccessary for keeping the 
body temperature. 
 
Figure 10 – Effects of leptin 
 
 
 
Surprisingly, leptin has an affect on reproductive system. It 
enhances reproductive functions probably by increasing the secretion of 
gonadotropin RH and LH and FSH 
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Leptin also enhances immune functions. It’s also said to modulate 
the development of atherosclerosis. That could be exactly due to the 
different lymphocytes response. [8] 
 
Among the less discussed function is the role in angiogenesis and 
the regulation of surfactant synthesis in fetal lungs. 
 
2.2.3. Epidemiology 
What the epidemiology of leptin variations concerns, it needs to be 
said, that the mutation in Ob gene (the gene for leptin protein) or leptin 
receptor are very rare. [9] 
 
It was proved that obese people have higher levels of leptin in their 
blood.  
 
Figure 11 – Leptin levels in obese 
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Since they’re obese it shows that leptin is not having it’s effect and 
this phenomenon is explained as leptin resistance. Studies suggest that 
the development of leptin resistance depends on the type of diet, not just 
on the final body fat percentage. In rodents, leptin resistence reached 
higher level if fructose was administered at higher ratio in diet. [10] 
 
 
2.3. Adiponectin 
2.3.1. General description 
Adiponectin is a hormon secreted exclusively from adipose tissue. It 
has a relatively high plasma levels – 0,01% of all proteins, i.e. 5-10 ug/ml. 
It’s level in blood is negatively corellated with body fat percentage – it‘s 
reduced in diabetic subjects and weight reduction increases adiponectin. 
It’s levels are higher in females than in males. [11] 
 
 
2.3.2. Effects 
Adiponectin is supressing metabolic derrangement that can cause 
diseases such as diabetes type 2, endotelial dysfunction and subsequent 
atherosclerosis, metabolic syndrome and nonalcoholic fatty liver disease. 
It does so by influencing metabolic pathways of energy substrates. It 
influences beta oxidation (thus changing RQ) and triglyceride clearance, 
gluconeogenesis, glucose uptake. As a result, it’s also improving insulin 
sensitivity. [12] The final result of all above stated changes is weight loss. 
But adiponectin exerts it’s weight reduction potential via brain too. [13] 
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Figure 12 – Proposed salutary effects of adiponectin 
 
 
 
2.3.3. Epidemiology  
Variants in the adiponectin gene influence adiponectin levels, 
adiposity and plasma lipid levels. A haplotype in the adiponectin gene 
promoter (-11391, -10068 and -4521) was significantly associated with 
higher plasma adiponectin levels in non-hispanic white. [14] 
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3. THE  NUGENOB STUDY FOLLOW-UP 
3.1. The NUGENOB study 
We took an advantage of an existing subjects database created in 
2003 under the EU-funded project called Nugenob. The name stands for 
„Nutrient-Gene interactions in human obesity – implications for dietary 
guidelines“. There where 770 participants of caucasian origin in the study 
– 607 women and 163 men. 
 
 
3.2. Methods 
They met the criteria which were age between 20 and 50 and BMI 
of 30 or over. Excluded were those who experienced a weight change of 
more than 3 kilograms in tha past 3 months, those who had hypertension, 
diabetes or hyperlipidemia on medication, untreated thyroid gland disease, 
surgically treated obesity, those who were pregnant at the time of the 
study, drug users and alcohol drinkers and those who were taking part in 
any other weight loosing programme or study. In the group of slim 
individuals, also those who had a history of BMI higher than 25 or history 
of any medication use except for contraceptive pills and medication for 
treatment of any chronic illness. Participants were hired through the media 
or were refered by their general practitioner or any other medical personell 
or institution in the United Kingdom, Netherlands, France, Spain, Czech 
republic, Sweden and Denmark. The protocol was approved by an ethical 
committee and each participant signed the conscent before the study 
started. 
 
The measurements were taking place in the local centrers in the 
above stated countries. All the participants underwent a 1-day clinical 
examination. On the day the study started, they came to the laboratory at 
8am after 12 hour fasting and 3 days of a regime that consisted of 
participant’s regularly diet, alcohol restriction and an excessive physical 
activity. After emptying the urinary bladder the subjects were taken their 
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anthropometrical measures. The height was taken with no shoes and 
using a standardized weight measuring device. The weight was measured 
three times with underwear on only and the average was used in the 
following calculations. The waist and hip circumference was measure in 
the underwear that is not any compressive. Thenafter, the body 
composition was evaluated in the subject in a supine position, using a 
multi-frequency bioimpedance (Bodystat, Quadscan 4000, Isle of Man, 
British Isles.) The participants where also taken blood tests for glucose, 
cortisol, free fatty acids, triglycerids, insulin-like growth factor-I and leptin 
and 39 randomly selected individuals were also tested for adiponectin 
levels.  
 
As a part of the study, further assesment was made including 
questionnaires investigating dietary habits, lifestyle etc. Further 
measurements including basal metabolic rate, respiratory quotient and 
energy expenditure and dynamics of various metabolits in the bloodstream 
in a fasting state and then 3 times in 1 hour intervals after drinking a high 
fat meal (95% fat from which 60% were saturated fatty acids, 3% 
carbohydrates and 2% proteins) in the amount counting for one half of the 
basal metabolic energy expenditure. The drink had to be drunk in less 
than 10 minutes. But since these details are not our data input source and 
were prooved to have no statistically significant effect on the measures 
obtained later in the study, I’m not going to describe the techniques of 
those measurements any further. 
 
Then the individuals underwent a 10-week hypocaloric dietary 
programme under which they were randomly divided into 2 group with 
eather low fat/ high carbohydrate diet (20-25% of energy from fat, 15% of 
energy from protein, 60-65% of energy from carbohydrate) or high fat/ low 
carbohydrate diet (40-45%, 15%, 40-45% of energy income in the same 
respective groups of nutrients). The subjects were tested again 10 weeks 
after the study started and for most of the collaborating centers that was 
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the end of data gathering. For adiponectin, only the previously selected 40 
individuals were retested.  
 
The Department of Sport Medicine at the 3rd Faculty of  Medicine at 
Charles University in Prague has decided to use their patient database 
from the Nugenob study and retest the patients 1 year after the intitial 
study started. Then, the methods were the same as in the initial study, 
except the adiponectin measurement, which were not performed. 
 
All the data gathered were analysed using SPSS 16.0.0 software. In 
the analysis we created a new variable, leptin-resistance-index, as a ration 
between leptin levels and fat mass. 
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3.3. Results 
 
Figure 13 - Descriptive statistics – mean values and standard deviations 
 
 baseline 10 weeks 1 year 
weight [kg] 100,52 ± 16,59 93,65 ± 16,43 95,24 ±15,15 
waist [cm] 106,11 ± 12,90 99,55 ± 12,76 102,59 ± 12,46 
hip [cm] 119,38 ± 10,33 114,43 ± 10,82 117,01 ± 8,16 
FFM [kg] 59,45 ± 11,57 58,00 ± 11,34 57,68 ± 9,56 
FM [kg] 41,14 ± 11,76 35,81 ± 11,89 36,82 ± 8,77 
leptin [ng/ml] 29,38 ± 15,25 20,08 ± 12,96  
adiponectin [ug/ml] 15,98 ± 11,05 15,57 ± 10,26  
 
 
Higher baseline leptin is associated with lower reduction of weight, 
waist and fat mass between the beginning and the 10th week. 
 
Higher baseline leptin-resistance-index is associated with lower 
reduction of weight, waist and fat mass between the beginning and  the 
10th week. 
 
Higher decrease of leptin between the beginning and the 10th week 
was associated with higher increase of fat mass between the 10th week 
and 1 year. 
 
Higher decrease of leptin-resistance-index between the beginning 
and the 10th week was associated with higher increase of fat mass 
between the 10th week and 1 year. 
  
Nor baseline adiponectin neither it’s change between the baseline 
and the 10th week are associated with any of the investigated 
anthropometric measures. 
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Association between baseline leptin and reduction of 
anthropometric measures between the baseline and the 10th week are: 
with weight reduction  (r = -0,149; p < 0,000), waist reduction (r = -0,144; p 
< 0,000) and fat mass reduction (r = -0,66; p = 0,98). 
 
Association between baseline leptin-resistance-index and reduction 
of anthropometric measures between the baseline and the 10th week are: 
with weight reduction (r = -0,180; p < 0,000), waist reduction (r = -0,150; p 
< 0,000) and fat mass reduction (r = -0.176; p< 0,000). 
 
Association between decrease in leptin between baseline and 10th 
week and fat mass increase between the 10th week and 1 year shows r = 
0,202, p = 0,64). 
 
Association between decrease in leptin-resistance-index between the 
baseline and the 10th week and fat mass increase between the 10th week 
and 1 year shows r = 0,231, p = 0,34. 
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3.4. Discussion 
Leptin is supposed to help in weight and fat mass reduction. But 
here we can see that the association was negative. That could be 
explained by the phenomenon of leptin resistance. That means that leptin 
resistance is higher when there’s more leptin on each weight unit of fat 
mass. In this state, leptin can not excert it’s influence in the body. One of 
the putative effects is an influence on central nervous system through 
which leptin stimulates sympatoadrenergic system and thus increases 
energy expenditure and eases weight loss.  
 
The above stated assumption is supported by our results of 
correlation analyses between anthropometrical changes and leptin-
resistance-index, which we counted as a ration of leptin levels and fat 
mass. 
 
 
Contrary, decrease in leptin till the 10th week is associated with 
increase of fat mass till 1 year. One of the possible explanation could be, 
that after 10 weeks of weight reduction program, leptin resistance 
disappeared and then, leptin could excert it’s full potential. If at this time, 
leptin was lower, it could not stimulate sympatoadrenergic system so much 
and that resulted in increase of fat mass. Another possible explanation is, 
that in subjects, where baseline leptin was higher, it was easier to 
decrease it. But after the end of weight reduction programme these 
patients came back to their lifestyle and gained more fat mass as they 
were getting back to the state from which they started at baseline. 
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Again, the above stated analyses was consistent with analyses of 
correlation between leptin-resistance-index and anthropometric changes 
between 10th week and 1 year. 
 
What adiponectin concerns, the fact that none of the investigated 
anthropometrical parameters was in a significant correlation with baseline 
adiponectin level and it’s dynamic, could be due to the fact, that in our 
study of less then 40 patients, adiponectin changes between baseline and 
the 10th were very minor (average baseline adiponectin level was 15,98 ± 
11,05 and at 10 weeks it was 15,57 ± 10,26). 
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Conclusion 
In this study I tried find a tool of recognizing high risk patients at the 
beginning of a weigh losing programme so that they could receive more 
care and finally achieve satisfactory results just as the other patients.   
 
I found out, that high leptin at the beginning is a risk factor for worse 
outcome after 10 weeks (i.e. lower weight loss, lower waist circumference 
reduction and lower fat mass reduction) and explained this by the 
existence of leptin resistance, a state in which body is insensitive to the 
effects of leptin, which is in general known to decrease body weight. Thus, 
improving leptin effects in secondary prevention, i.e. weigh reduction 
programmes in obese and overweight patients, could have a positive 
outcome. 
The first possibility would be leptin administration. Even this method 
could be reasonable just as insulin administration in diabetes type 2 
patients who are impossible to be compensated with the use of peroral 
antidiabetics. But just as in the case of diabetes type 2, more reasonable 
treatment would be administration of leptin-sensitizing substance. Some 
studies suggest that amylin, hormon produces by pancreatic beta cells, is 
an important leptin sensitivity enhancer. [15] 
  
 I also found out that decrease in leptin after 10 weeks of low-calorie 
diet programme was a risk factor for a long term (1 year) outcome. One of 
the explanations could be, that after fasting period, leptin sensitivity is 
restored and then, by the time leptin can fully excert it’s potential in weight 
and fat mass losing proceses, it’s low levels are associated with worse 
outcome. Here, after the leptin sensitivity is restored, even leptin 
administration would be a potential tool of improving the results of 
secondary prevention, i.e. it would help the previously obese patients who 
lost some weight to keep it and not regain it. 
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Unfortunatelly, adiponectin did not prove to be a good predictor of 
anthropometrical changes in our study. But this could be due to our 
relatively small patient population for adiponectin testing, which was 
smaller than 40 individuals. But adiponectin is know to be in a positive 
correlation with better metabolic state. Thus, increasing adiponectin by 
medications such as thiazolidinediones (throught PPAR activation) [16] 
could be reasonable and have a positive effect in prevention of 
complications of obesity. The issue of influence of adiponectin deserves 
more attention and should be further investigated by another study 
involving more then just 40 patients. 
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Summary 
 In prior times, storing fat was an important capability of human body 
that helped to survive. But these days, human in the developt countries do 
not lack energy from nutrition any more and fat storing processes lost 
much of their benefits and are showing their costs in the form of obesity 
and it’s complications. 
 
 Obesity is a stage of increased body fat content. It’s defined using a 
ratio betwen body weight and square of body height, so called body mass 
index, BMI. Obesity is represented by BMI higher then 25. 
 
 In the Czech republic, about 20% of women and 16% of men are 
obese. Similar situation is in the most developed countries, topped by the 
USA, where about 30% of the population are meeting the obesity criterion. 
 
 In the etiology of obesity, we can distinguish internal and external 
factors. What the internal factors concerns, obesity could be either 
secondary to another disease, which is relativelly rare or primary. Primary 
obesity is in a very small number of cases caused by an monogenic 
inherited pattern. Most often it’s caused by a failure of body regulation 
processes. That means a dysbalance between energy intake and energy 
expenditure. And it just this balance that’s also disrupted by external 
factors. In tha last decades, energy intake was made very easy for our 
population but energy expenditure decreased with the change from 
manual labour to sedentary lifestyle such as administrative work. 
 
 Obesity comes with a number of complications. Among them are 
diabetes mellitus type 2, hypertension, atherosclerosis, depression, 
reproductive disorders, arthrosis and others. Thus, preventing and treating 
obesity has a major effect on the health outcome. 
 
36 
 In order to achieve better results in weight reduction efforts, the 
treatment of obesity needs to run on an individual basis. Each patient 
needs to be first assessed in term of his anthropometrical, biochemical 
and psychological measures and then an individual goal needs to be 
established. 10% weight loss in 6 months is seen as a minimum. The 
treatment always starts with lifestyle changes. If those fail, 
pharmacological treatment take place. In the most severe cases, also 
surgical treatment come available. 
 
 But even if a considerable weight loss is achieved, weight 
maintenance is still a major problem. In order to help with this issue, we’ve 
decided to try to find predictors of weight maintenance parameters so that 
patients in higher risk could receive more attention. 
 
  The role of adipokines, leptin and adiponectin, is broadly discussed. 
These two substances were the main object of interest in our study, too. 
 
Leptin is secreted mainly from adipocytes and it’s levels increase 
with cell fat content and body fat percentage. Leptin itself is supposed to 
lead to weight loss, both by decreasing appetite and increasing energy 
expenditure. But high levels of leptin can be a signal of so called leptin 
resistance, a state in which leptin is losing it’s effects. 
 
Adiponectin is secreted exclusively from adipose tissue. In obese 
people, lower levels of adiponectin were proven (i.e. adiponectin levels are 
in a negative correlation with body fat percentage). That’s consistent with 
the fact that adiponectin is affecting a range of metabolic prosesses and 
thus improves insulin sensitivity and metabolic profile. 
 
 
For evaluation, we used a obese patient database (of almost 750 
subjects), that was build under the Nugenob study, conducted in 8 cities in 
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7 european countries (Denmark, the Netherlands, Sweden, Great Britain, 
Czech republic, France (2 centers) and Spain. The study consisted of 
many different measurement. What is important for this thesis, all the 
participants were measured their anthropometric and biochemical 
parameters at the baseline and 10 weeks later, at the end of a 
standardized weight reduction program. 1 year after the initial study, 
approximatelly 100 subjects were retested for their anthropometrical 
measures in the laboratory of Department of Sport medicine, 3rd Faculty of 
Medicine, Charles University in Prague. Based on the data gathered, we 
tried to determine whether leptin and adiponectin levels in the initial study 
could be used as predictors for the measures taken 1 year later. 
 
 
I found out, that higher baseline leptin and the ratio between leptin 
and fat mass (which we named leptin-resistance-index) is a risk factor for 
worse outcome after 10 weeks of low-calorie diet. This could be explained 
by the phenomenon of leptin resistance, in which leptin can not excert it’s  
potential and help in weight and fat mass reduction. Thus, I suggest that 
recognizing patients with high leptin or leptin-resistance-index at the 
beginning of weigh reduction programmes that are part of secondary 
prevention of obesity (i.e. prevention of obesity complications), could be 
useful. These patients may need to receive extra attention and care in 
order to achieve satisfactory results. A part of this care could be 
administration of some leptin sensitizing agent (e.g. the putative leptin 
sensitizer – amylin.) [15] 
 
I also recognized a bigger decrease of leptin and leptin-sensitivity-
index between baseline and 10th week as a risk factor for a worse 
outcome between 10th week and 1 year. Here the worse outcome was 
represented by higher increase in fat mass. This could be explained as a 
lack of leptin after leptin sensitivity was restored by 10 weeks of low-
calorie diet. Also these patients could receive an extra care as a part of 
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secondary prevention of obesity, and could be for example administered 
leptin. 
 
I did not find any significant correlation between adiponectin and the 
anthropometrical measures investigated. I suggest that this could be due 
to lower patient database (40 subjects) and the fact that in this patient 
population, adiponectin changes between baseline and 10th week were 
not any significant. But since adiponectin is known to have a positive effect 
on the general metabolic state, it’s role in changes of anthropometric 
measure in obese patient in secondary prevention of obesity should be 
deeply investigated in a study involving more patients. 
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Souhrn 
 Schopnost ukládat energii ve formě tuku byla v minulosti velmi 
důležitá pro přežití. Ale v dnešní době, kdy již nedostatkem potravy 
netrpíme, tato schopnost pozbyla mnohé ze svých výhod a naopak se 
objevily její stinné stránky v podobě obezity a jejích komplikací. 
  
 Obezita je spojena s větším obsahem tuku v těle a je obvykle 
definována pomocí poměru tělesné hmotnosti a druhé mocniny tělesné 
výšky, tzv. body mass indexu, BMI. Jako obezita je označen stav s BMI 
nad 25. 
 
 V České republice trpí obezitou asi 20% žen a 16% mužů. Podobná 
situace je ve většině vyspělých zemí. Například v USA je prevalence 
obezity až 30%. 
 
 Na rozvoji obezity se podílí vnitřní a vnější faktory. Mezi vnitřní 
faktory se řadí například genetická výbava, která může způsobit vzácnou 
dědičnou primární obezitu, nebo různé nemoci, u kterých se obezita rozvíjí 
sekundárně . Nejdůležitějšími vnitřními faktory jsou ale parametry 
systému řídícího rovnováhu příjmu a výdeje energie. Tuto rovnováhu 
kromě vnitřních faktorů ovlivňuje výrazně i vnější prostředí. To se v 
posledních desetiletích hodně změnilo ve smyslu přechodu z fyzické práce 
na prace sedavou, se kterou se pojí nižší energetický výdej. 
 
 S obezitou se pojí celá řada komplikací. Patří mezi ně diabetes 
mellitus 2. typu, hypertenze, ateroskleróza, deprese, poruchy reprodukce, 
artróza nosných kloubů aj. Prevence a léčba obezity je proto důležitým 
cílem v péči o zdraví. 
 
 K léčbě obezity je nezbytné přistupovat individuálně. Je potřeba 
nejdříve posoudit fyzické, biochemické i psychické parametry pacienta a 
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potom stanovit reálný cíl léčby, kterým by měl být vždy úbytek minimálně 
10 procent váhy za 6 měsíců. Jako první přichází na řadu režimová 
terapie a teprve v případě, že selže, dostává se ke slovu farmakoterapie, 
ev léčba chirurgická.  
  
 Obtížné ale není pouze snížení váhy, ale také jejich udržení. Právě 
na něj jsem se zaměřil ve své práci a snažil se najít klíč k včasnému 
rozpoznání pacientů, kteří jsou ve větším riziku opětovného příbytku váhy, 
aby bylo možné těmto pacientům včas pomoci.  
 Účinky adipokinu, leptinu a adiponektinu, jsou v dnešní době široce 
diskutovaným tématem. I já jsem se na ně ve své práci zaměřil. 
 
Leptin je hormon sekretovaný hlavně adipocyty. Jeho sekrece se 
zvyšuje s množstvím tělesného tuku a obsahem tuku v buňkách. Leptin 
působí pozitivně na úbytek váhy, jak prostřednictvím zvýšení 
energetického výdeje v periferních tkáních, tak snížením příjmu potravy. 
Vysoké hladiny leptinu se ale mohou pojit se stavem, který se nazývá 
leptinovou rezistencí, kdy se účinky leptinu projevují jen v omezené  míře. 
 
Adiponektin je produkován výhradně tukovou tkání. Bylo 
prokázáno, že hladiny leptinu jsou nižší u obézních pacientů v porovnání 
s normální populací. To může souviset s tím, že adiponektin má pozitivní 
vliv na mnoho metabolických procesů a zlepšuje inzulínovou citlivost a 
metabolický profil a proto je jeho nedostatek predispozicí pro metabolická 
onemocnění. 
 
 Pro svou práci jsem využil data získaná v rámci projektu Nugenob, 
který probíhal v 8 evropských městech a kterého se účastnilo přibližně 750 
osob. V rámci studie prošli dobrovolníci desetitýdenní dietní intervencí. 
Před začátkem intervence a po jejím skončení byli všichni vyšetření. Byla 
odebrána kompletní antropometrie (výška, váha, obvod pasu, boků), 
změřeno množštví tělesného tuku a netukové hmoty, odebrána krev pro 
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stanovení řady parametrů včetně hladin leptinu a u 40 osob také 
adiponektinu. Pro většinu výzkumných center tím studie skončila. Ústav 
tělovýchovného lékařství ale ve studii pokračoval a pozval si pacienty ze 
své datábáze na kontrolu výše zmíněných parametrů ještě po 1 roce od 
ukončení původní studie. Na základě takto získaných dat jsem se snažil 
odhalit možnost predikce změn antropometrie na základě hladin leptinu a 
adiponektinu. 
 
Zjistil jsem, že vyšší počáteční hodnota leptinu, stejně tak jako vyšší 
poměr leptinu a tukové hmoty (coby ukazatel leptinové rezistence) souvisí 
z menším úbytkem hmotnosti, obvodu pasu a tukové hmoty po 
desetitýdenní dietní intervenci. Jedním z možných vysvětlení je, že vysoký 
leptin ukazuje na již zmíněnou leptinovou rezistenci, která snižuje účinek 
leptinu ve smyslu snížení váhy a tukové hmoty. Vyšší hodnoty leptinu 
nebo poměru leptinu a tukové hmoty by tedy mohly sloužit jako ukazatel, 
podle kterého by bylo možné rozpoznat rizikové pacienty v rámci 
sekundární prevence obezity, tzn. prevence komplikací, a takovým 
pacientům věnovat zvýšenou pozornost, aby i oni dosáhli požadovaných 
výsledků. Jednou z možných intervencí je podání látky zlepšující 
leptinovou rezistenci. Podle některých studií by pro to byl vhodný amylin, 
látka produkovaná pankreatem. [15] 
 
Jako rizikový se ukázal být větší pokles leptinu nebo poměru leptinu 
a tukové hmoty mezi začátkem studie a 10. týdnem, který se pojil s větším 
nárůstem množství tukové tkáně mezi 10. týdnem a 1 rokem. To je možné 
vysvětlit tím, že po dietní intervenci byla obnovena leptinová rezistence a 
proto nižší hladiny leptinu opravdu odpovídaly nárůstu množštví tukové 
tkáně. I tuto skutečnost je možné využít v rámci sekundární prevence 
obezity. Rizikoví pacienti by mohli například absolvovat terapii leptinem. 
 
 Mezi hladinou adiponektinu a sledovanými antropometrickými 
parametry jsem neobjevil žádnou signifikantní korelaci. To si vysvětluji 
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také malým souborem pacientů (40 osob) a skutečností, že změna hladiny 
adiponektinu mezi začátkem studie a 10. týdnem nebyla signifikantní. O 
adiponektinu je nicméně známo, že má pozitivní efekt na metabolický 
profil. Jeho možnosti v sekundární prevenci obezity by tedy neměly ujít 
dalšímu zájmu a bylo by vhodné věnovat se této problematice ve studii 
s větším počtem osob. 
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